Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Srl & Shizuoka Cancer Center Collaborative Laboratories Inc. currently manages a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The data shows 1 pending office action, which is handled by a single examining professional. This indicates a narrow focus for the company's current legal interactions at the patent office. The presence of 1 distinct examiner and 1 distinct art unit suggests that the pending matters are confined to a specific technical niche within the broader biotechnology sector.
The busiest examiner for this portfolio is GOLDBERG, JEANINE ANNE, who is responsible for 1 busiest examiner pending office action. Because the total count of pending actions is also 1, this individual holds the entirety of the company's active prosecution workload. For a practitioner, this means that the outcome of the portfolio's current prosecution phase depends on the interactions with this one person. The concentration in a single art unit further simplifies the procedural landscape, as the company does not have to navigate varying standards across different administrative divisions at this time.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GOLDBERG, JEANINE ANNE | 1 | 45.4% | +40.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18685363 | METHOD FOR DETECTING GENE MUTATION AND METHOD FOR DIFFERENTIATING SOMATIC CELL MUTATION FROM GERM CELL LINE MUTATION | GOLDBERG, JEANINE ANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18685363 | METHOD FOR DETECTING GENE MUTATION AND METHOD FOR DIFFERENTIATING SOMATIC CELL MUTATION FROM GERM CELL LINE MUTATION | GOLDBERG, JEANINE ANNE | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18685363 | METHOD FOR DETECTING GENE MUTATION AND METHOD FOR DIFFERENTIATING SOMATIC CELL MUTATION FROM GERM CELL LINE MUTATION | GOLDBERG, JEANINE ANNE | 1682 | §101§103§112 | Final Rejection | — | Pending | Feb 21, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSrl & Shizuoka Cancer Center Collaborative Laboratories Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jeanine Anne Goldberg has the most, with 1 of Srl & Shizuoka Cancer Center Collaborative Laboratories Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
